New insider activity at Heron Therapeutics ( (HRTX) ) has taken place on August 12, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Rubric Capital Management LP has made a substantial investment in Heron Therapeutics by purchasing 2,387,225 shares, valued at $3,580,837. Additionally, Director Adam Morgan has acquired 1,766,546 shares of the company, with a total purchase value of $2,649,819.
Recent Updates on HRTX stock
Heron Therapeutics recently reported its Q2 2025 earnings, showcasing strong financial performance and strategic advancements. The company achieved a net revenue of $37.2 million for the quarter, with year-to-date revenues reaching $76.1 million. Despite a net loss of $2.4 million, this was an improvement over the previous year’s loss, indicating better financial management. Heron successfully completed new financing arrangements, enhancing its financial flexibility. Demand for its products, ZYNRELEF and APONVIE, showed significant growth, and the transition to a permanent J-code for ZYNRELEF is expected to streamline reimbursement processes and support broader adoption. The oncology franchise also outperformed expectations, contributing to the company’s positive outlook. Heron reaffirmed its 2025 net revenue guidance and raised its adjusted EBITDA guidance, driven by strategic sales force enhancements and product demand growth.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics’ overall stock score is primarily influenced by its financial performance challenges and bearish technical indicators. However, positive earnings call insights and strategic initiatives provide some optimism for future growth.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
YTD Price Performance: -20.0%
Average Trading Volume: 1,525,055
Technical Sentiment Signal: Strong Sell
Current Market Cap: $196.2M